Loading
Before some cancer drugs you are given other medicines, usually a steroid such as dexamethasone and an antihistamine, to lower the chance of a reaction during the drip. For docetaxel the steroid tablets start the day before, so it matters that you take them as told. Many drugs need no premedication at all.
ESMO (2017) recommends premedication with corticosteroids plus antihistamines before every taxane [IV, A]. For paclitaxel it gives intravenous dexamethasone with diphenhydramine 50 mg and an H2 antagonist 30 minutes before [II, A], noting a randomised trial in which short intravenous dexamethasone matched oral dexamethasone for reactions with fewer side effects [II, A]; the US label gives oral dexamethasone 20 mg 12 and 6 hours before, with diphenhydramine and an H2 antagonist 30 to 60 minutes before. For docetaxel the label and ESMO give oral dexamethasone 8 mg twice daily for 3 days starting the day before (8 mg at 12, 3 and 1 hours before in prostate cancer), against fluid retention as well as reactions.
For platinums ESMO does not routinely recommend premedication (consider in high-risk patients; it may not prevent a reaction) [IV, B]. For antibodies it varies by drug: rituximab always with an antipyretic and antihistamine [IV, A], with glucocorticoids considered in lymphoma and CLL; cetuximab with a corticosteroid plus antihistamine [IV, B], which can stop after the second infusion if no reaction; daratumumab with an intravenous corticosteroid, an antipyretic and an antihistamine before every infusion and oral corticosteroid on the two days after [IV, B]; none recommended for trastuzumab, bevacizumab, panitumumab or atezolizumab [IV, B]. Bleomycin in lymphoma starts with two doses of 2 units or less [IV, B]. ESMO asks nurses to check that oral premedication was taken [V, C]. Severe reactions still occur despite premedication (paclitaxel 2 to 4%).
Why: Without premedication about three in ten people react to paclitaxel or docetaxel; with it, severe reactions fall to a few in a hundred.
“All patients should receive premedication with corticosteroids plus antihistamines before taxane administration”
Why: Paclitaxel reactions are mostly caused by histamine release, so blocking both histamine receptors and adding a steroid prevents most of them.
“One dose of i.v. dexamethasone plus diphenhydramine (50 mg i.v.) and a H2 receptor antagonist (ranitidine 50 mg or cimetidine 300 mg i.v.) 30 min before paclitaxel infusion”
Why: The steroid lowers both the risk of an allergic reaction and the fluid build-up docetaxel can cause.
“All patients should be premedicated with oral corticosteroids (see below for prostate cancer) such as dexamethasone 16 mg per day (e.g., 8 mg twice daily) for 3 days starting 1 day prior to docetaxel injection administration in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions”
Why: Missed tablets are a common and avoidable reason for a reaction.
“If premedications are to be taken orally, oncology nurses should check that the patient has actually taken them”
Why: Most people react to the first rituximab dose, mainly through cytokine release; a slow start and premedication make reactions milder.
“Premedication consisting of an antipyretic and an antihistamine should always be given”
Why: Reactions affect up to half of patients, mostly at the first infusion.
“Premedication 1 h before every infusion: i.v. corticosteroid [(methyl)prednisolone 100 mg, or equivalent], oral antipyretics (paracetamol 650–1000 mg) and oral or i.v. antihistamine (diphenhydramine 25–50 mg or equivalent).”
Why: Platinum reactions are true allergies that build up over many cycles, and steroids and antihistamines do not reliably stop them.
“Corticosteroids and H1/H2 antagonists not routinely recommended. Consider in high-risk patients. Premedication may not prevent an IR.”
Why: Bleomycin can rarely cause a sudden severe reaction in people with lymphoma, so small first doses test for it.
“Because of the possibility of an anaphylactoid reaction, lymphoma patients should be treated with 2 units or less for the first 2 doses. If no IR occurs, then the regular dosage schedule may be followed”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Premedicate by drug, not by habit: corticosteroid plus antihistamine before every taxane (ESMO [IV, A]); for paclitaxel a single intravenous dexamethasone dose with H1 and H2 blockade 30 minutes before (ESMO [II, A]), where the US label instead gives oral dexamethasone 12 and 6 hours before; for docetaxel three days of oral dexamethasone from the day before (label; ESMO [IV, B]); antipyretic and antihistamine always before rituximab (ESMO [IV, A]); per-infusion steroid, antipyretic and antihistamine before daratumumab (ESMO [IV, B]); none routinely before platinums, trastuzumab, bevacizumab, panitumumab or PD-L1 antibodies (ESMO [IV, B]). Check oral premedication was taken.
ESMO (Annals of Oncology, Roselló et al.) 2017 · US Food and Drug Administration label (DailyMed) 2026 · US Food and Drug Administration label (DailyMed) 2026
Where it differs: Gives dexamethasone 20 mg by mouth about 12 and 6 hours before paclitaxel instead of one intravenous dose just before.
Evidence: This is the US label's regimen. ESMO cites a randomised trial that found no difference in reaction rates between oral and short-term intravenous dexamethasone before a first paclitaxel cycle, with fewer side effects from the intravenous dose [II, A].
US Food and Drug Administration label (DailyMed) 2026 · ESMO (Annals of Oncology, Roselló et al.) 2017
Where it differs: Gives corticosteroid and antihistamine before the first two cetuximab infusions only, if neither causes a reaction.
Evidence: ESMO [IV, B]; it reports corticosteroids plus antihistamines reduced grade 3 or 4 reactions to 1%, compared with 4.7% with antihistamines alone.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Corticosteroid plus antihistamine before every taxane | [IV, A] | ESMO (Annals of Oncology, Roselló et al.) 2017 |
| Paclitaxel: one intravenous dexamethasone dose with H1 and H2 antagonists 30 minutes before | [II, A] | ESMO (Annals of Oncology, Roselló et al.) 2017 |
| Short intravenous dexamethasone as effective as oral, with fewer side effects “However, short-term i.v. dexamethasone was associated with fewer side-effects than oral dexamethasone” | [II, A] | ESMO (Annals of Oncology, Roselló et al.) 2017 |
| Antipyretic and antihistamine always before rituximab | [IV, A] | ESMO (Annals of Oncology, Roselló et al.) 2017 |
| Cetuximab: corticosteroid plus antihistamine; may stop after the second infusion without a reaction “Premedication can be discontinued after the second infusion if no IR is observed” | [IV, B] | ESMO (Annals of Oncology, Roselló et al.) 2017 |
| Platinums: premedication not routinely recommended | [IV, B] | ESMO (Annals of Oncology, Roselló et al.) 2017 |
| Trastuzumab: premedication not recommended “Loading dose in 90 min. Subsequent doses in 30 min. Premedication is not recommended.” | [IV, B] | ESMO (Annals of Oncology, Roselló et al.) 2017 |
| Paclitaxel: all patients premedicated (US label) “All patients should be premedicated prior to paclitaxel injection administration in order to prevent severe hypersensitivity reactions.” | Product labelling (not graded) | US Food and Drug Administration label (DailyMed) 2026 |
Shares Infusion reactions, hypersensitivity and extravasation, Oxaliplatin, Rituximab, Paclitaxel / nab-paclitaxel.
Shares Cetuximab, Docetaxel, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Infusion reactions, hypersensitivity and extravasation, Anticancer treatment prescribing and pharmacy verification before each cycle.
Shares Oxaliplatin, Docetaxel, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Anticancer treatment prescribing and pharmacy verification before each cycle, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Oxaliplatin, Cetuximab, Docetaxel.
Shares Oxaliplatin, Docetaxel, Carboplatin.
Shares Infusion reactions, hypersensitivity and extravasation, Oxaliplatin.